Fannie Mae, Freddie Mac shares tumble after conservatorship comments
SECAUCUS, N.J.—Michael E. Prevoznik, Senior Vice President and General Counsel at Quest Diagnostics Inc. (NYSE:DGX), recently executed a notable stock transaction. According to an SEC filing, Prevoznik sold 604 shares of Quest Diagnostics common stock on February 20, 2025, at an average price of $170.99 per share, amounting to a total of $103,277. This sale was conducted under a pre-established Rule 10b5-1 trading plan. The transaction comes as Quest Diagnostics, with a market capitalization of $19.2 billion, trades near its 52-week high of $172.64. InvestingPro analysis indicates the stock is currently in overbought territory.
In a separate transaction on February 19, 2025, Prevoznik disposed of 374 shares at $169.71 each to cover tax obligations related to the vesting of restricted stock units, totaling $63,471. Following these transactions, Prevoznik holds 39,845 shares directly and 5,641 shares indirectly through the company’s 401(k) and Supplemental Deferred Compensation Plan. The stock has shown strong momentum with a 38.7% return over the past year. Get deeper insights into Quest Diagnostics’ valuation and 10+ additional exclusive tips with InvestingPro.
In other recent news, Quest Diagnostics reported strong financial results for the fourth quarter of 2024, exceeding earnings expectations with an adjusted earnings per share (EPS) of $2.23, surpassing the forecast of $2.19. The company’s revenue also outperformed projections, reaching $2.62 billion against the anticipated $2.58 billion. This performance was driven by a 14.5% year-over-year increase in consolidated revenues, with notable growth in advanced diagnostics and preventative health services. Despite this positive outcome, the 2025 adjusted EPS guidance was slightly below expectations due to higher interest expenses and share count assumptions. JPMorgan responded by raising Quest Diagnostics’ price target to $180 from $173, maintaining a Neutral stock rating. The firm also adjusted its financial estimates for 2025, increasing the revenue forecast to $10.776 billion and the adjusted operating income estimate to $1.736 billion. Looking further ahead, the 2026 adjusted EPS estimate has been raised to $10.56, reflecting a stable growth outlook for Quest Diagnostics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.